Researchers at Georgetown University Medical Center say they are moving closer to understanding why the most lethal form of human malaria has become resistant to drug treatment in the past three decades.
Laundry workers, commercial fishermen and environmental and public health groups petitioned the EPA urging the agency to provide health and safety protections from the endocrine-disrupting chemicals, nonyplphenol and nonylphenol ethoxylates (NPEs).
The following is GlaxoSmithKline?s [NYSE:GSK] response to editorials written in the New England Journal of Medicine (NEJM) regarding Avandia? for the treatment of type 2 diabetes.
Paying hospitals extra money does not appear to significantly improve the way they treat heart attack patients or how well those patients do. But giving hospitals the information that they need to improve heart attack care does help.
Two research teams have developed models for classifying the clinical outcomes of patients with nonsmall cell lung cancer using mass spectrometry techniques. The studies are published in the June 6 Journal of the National Cancer Institute.
A multi-center team, led by Vanderbilt-Ingram Cancer Center investigators, has discovered a ?signature? of proteins in the blood that predicts which non-small-cell lung cancer patients will live longer when they are treated with certain targeted cancer therapies.
Divorce puts children at higher risk of Ritalin use compared to kids whose parents stay together, says new research by a University of Alberta sociologist, who cautions that this doesn?t necessarily mean that divorce is harmful to a child. The study appears in this week?s issue of the Canadian Medical Association Journal.
A new way to provide clear images of cancerous tumors in the kidney during surgery promises to help physicians preserve as much kidney function as possible while still removing all the malignant tissue — a significant advance as doctors discover that saving as much healthy kidney tissue as possible is crucial for the future health of cancer patients.
GlaxoSmithKline (GSK) today announced final results of a Phase II proof-of-concept clinical trial of its investigational MAGE-A3 Antigen-Specific Cancer Immunotherapeutic (ASCI) in MAGE-A3 positive patients with stage IB or II Non-Small Cell Lung Cancer (NSCLC).
A groundbreaking surgical therapy capable of stabilising and restoring vision in the vast majority of patients who currently suffer blindness through Age-Related Macular Degeneration is to be taken to clinical trial by scientists and clinicians at the UCL Institute of Ophthalmology, Moorfields Eye Hospital and the University of Sheffield.